advertisement
11.5.2 Topical (15)
Showing records 1 to 15
Display all abstracts in classification 11.5.2 Topical
Search within classification 11.5.2 Topical5677 A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients
Harris A; Arend O; Hak Sung Chung; Kagemann L; Cantor L; Martin B
Ophthalmology 2000; 107: 430-434
5786 Clinical investigation: Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma
Centofanti M; Manni G; Gregori D; Cocco F; Lorenzano D; Bucci MG
Graefe's Archive for Clinical and Experimental Ophthalmology 2000; 238: 302-305
5793 Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects
Brubaker RF; Ingram CJ; Schoff EO; Nau CB
Ophthalmology 2000; 107:283-287
5795 Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension: a three-month randomized study
Emmerich KH
Graefe's Archive for Clinical and Experimental Ophthalmology 2000; 238:19-23
5798 Twenty-four hour control of intraocular pressure with dorzolamide and timolol maleate in exfoliation and primary open-angle glaucoma
Konstas AGP; Maltezos A; Bufidis T; Hudgins AG; Stewart WC
Eye 2000; 14:73-77
5808 The ocular hypotensive effect of the combination of latanoprost with dorzolamide
Chiselita D; Apatachioae I; Poiata I
Oftalmologia 1999; 46:39-45
5821 Increased optic nerve head blood flow after one week of twice daily topical brinzolamide treatment in Dutch-belted rabbits
Barnes GE; Li B; Dean T; Chandler ML
Survey of Ophthalmology 2000; 44(Suppl 2):S131-S140
5822 Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension
Giasson CJ; Nguyen TQ; Boisjoly HM; Lesk MR; Amyot M; Charest M
American Journal of Ophthalmology 2000; 129:144-150
5823 The long-term safety and efficacy of brinzolamide 1.0% (azopt) in patients with primary open-angle glaucoma or ocular hypertension: the Brinzolamide Long-Term Therapy Study Group
March WF; Ochsner KI
American Journal of Ophthalmology 2000; 129:136-143
5824 Carbonic anhydrase inhibitors. Part 79. Synthesis of topically acting sulfonamides incorporating GABA moieties in their molecule, with long-lasting intraocular pressure-lowering properties
Mincione G; Menabuoni L; Briganti F; Mincione F; Scozzafava A; Supuran CT
European Journal of Pharmaceutical Sciences 1999; 9:185-199
5825 The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension: Brinzolamide Primary Therapy Study Group
Sall K; Assil KK; Beehler CC; Cacioppo L; Caine R; DiGaetano M; Friedlaender M; Friedland B; Greenidge K; Gross RL
Survey of Ophthalmology 2000; 44(Suppl 2):S155-S162
5826 Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy
Shin DD; Atlas W; Brotherman D; Caine R; Craven R; Gottlieb L; Kolodner H; Kraff C; Kranemann C; Krupin T
Survey of Ophthalmology 2000; 44(Suppl 2):S163-S168
5827 Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt): Brinzolamide Dose-Response Study Group
Silver LH
Survey of Ophthalmology 2000; 44(Suppl 2):S147-S153
5828 Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies: Brinzolamide Comfort Study Group
Silver LH
Survey of Ophthalmology 2000; 44(Suppl 2):S141-S145
5829 Carbonic anhydrase inhibitors (Part 78): synthesis of water-soluble sulfonamides incorporating beta-alanyl moieties, possessing long-lasting intraocular pressure lowering properties via the topical route
Supuran CT; Briganti F; Menabuoni L; Mincione G; Mincione F; Scozzafava A
European Journal of Medicinal Chemistry 2000; 35: 309-321